Equities Analysts Set Expectations for RCKT FY2026 Earnings

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) – Analysts at Lifesci Capital issued their FY2026 earnings per share (EPS) estimates for shares of Rocket Pharmaceuticals in a research note issued to investors on Thursday, February 26th. Lifesci Capital analyst P. Dolezal anticipates that the biotechnology company will post earnings of ($1.81) per share for the year. Lifesci Capital has a “Strong-Buy” rating on the stock. The consensus estimate for Rocket Pharmaceuticals’ current full-year earnings is ($2.83) per share.

RCKT has been the topic of several other research reports. Bank of America dropped their price target on shares of Rocket Pharmaceuticals from $10.00 to $8.00 and set a “buy” rating on the stock in a research note on Tuesday, November 18th. TD Cowen raised Rocket Pharmaceuticals to a “hold” rating in a report on Friday, December 19th. Wedbush reaffirmed an “outperform” rating and set a $16.00 target price on shares of Rocket Pharmaceuticals in a research note on Friday, November 7th. Wall Street Zen upgraded Rocket Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Saturday. Finally, JPMorgan Chase & Co. lowered Rocket Pharmaceuticals from a “neutral” rating to an “underweight” rating in a report on Tuesday, November 18th. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, six have assigned a Hold rating and three have issued a Sell rating to the stock. Based on data from MarketBeat, Rocket Pharmaceuticals presently has an average rating of “Hold” and a consensus price target of $14.50.

Rocket Pharmaceuticals Stock Up 10.6%

Rocket Pharmaceuticals stock opened at $5.01 on Monday. The company has a debt-to-equity ratio of 0.07, a quick ratio of 6.38 and a current ratio of 6.38. Rocket Pharmaceuticals has a one year low of $2.19 and a one year high of $9.73. The company has a 50-day simple moving average of $3.62 and a 200-day simple moving average of $3.45. The firm has a market capitalization of $543.94 million, a P/E ratio of -2.49 and a beta of 0.39.

Rocket Pharmaceuticals (NASDAQ:RCKT) last issued its earnings results on Thursday, February 26th. The biotechnology company reported ($0.38) earnings per share for the quarter, topping the consensus estimate of ($0.42) by $0.04. During the same period last year, the business earned ($0.62) earnings per share.

Insider Transactions at Rocket Pharmaceuticals

In related news, General Counsel Martin Wilson sold 12,253 shares of the stock in a transaction that occurred on Friday, February 13th. The shares were sold at an average price of $3.31, for a total transaction of $40,557.43. Following the completion of the sale, the general counsel directly owned 683,376 shares of the company’s stock, valued at $2,261,974.56. This represents a 1.76% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Gaurav Shah sold 12,279 shares of Rocket Pharmaceuticals stock in a transaction that occurred on Friday, February 13th. The stock was sold at an average price of $3.31, for a total transaction of $40,643.49. Following the completion of the transaction, the chief executive officer owned 1,052,045 shares in the company, valued at approximately $3,482,268.95. This trade represents a 1.15% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 29,415 shares of company stock worth $97,398. 24.76% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Rocket Pharmaceuticals

A number of hedge funds have recently modified their holdings of RCKT. Prudential Financial Inc. purchased a new stake in shares of Rocket Pharmaceuticals during the second quarter valued at $25,000. CANADA LIFE ASSURANCE Co raised its holdings in Rocket Pharmaceuticals by 94.4% during the 2nd quarter. CANADA LIFE ASSURANCE Co now owns 12,202 shares of the biotechnology company’s stock worth $29,000 after buying an additional 5,926 shares during the period. Corton Capital Inc. acquired a new stake in Rocket Pharmaceuticals during the 2nd quarter worth about $38,000. Franklin Resources Inc. purchased a new stake in Rocket Pharmaceuticals during the fourth quarter valued at about $38,000. Finally, Virtu Financial LLC acquired a new position in shares of Rocket Pharmaceuticals in the third quarter worth about $40,000. 98.39% of the stock is currently owned by institutional investors and hedge funds.

About Rocket Pharmaceuticals

Rocket Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing gene therapies for rare, inherited pediatric diseases. The company employs a proprietary adeno-associated virus (AAV) and lentiviral vector platform to deliver functional copies of genes in patients with genetic deficiencies. Its programs target a spectrum of disorders, including Fanconi anemia, leukocyte adhesion deficiency type I and Danon disease, with the goal of delivering one-time treatments that address the underlying causes of disease rather than merely managing symptoms.

The company’s pipeline comprises multiple product candidates in various stages of development.